Complete hematological response of CML to BRAF/MEK inhibition in a patient with metastatic melanoma

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Targeted MEK inhibition holds promise in BRAF V600E mutation-positive malignant melanoma, where cell growth through the MAP kinase (MAPK) pathway is well established. MAPK pathway activation is also important in chronic myeloid leukemia (CML) leukemogenesis. This case report suggests further eval...